CD274 and non-small cell lung carcinoma: All of the current FDA (U.S. Food and Drug Administration) and/or EMA (European Medicines Agency)-approved and ASCO (American Society of Clinical Oncology) and/or ESMO (European Society for Medical Oncology)-recommended immunotherapeutic drugs for the treatment of advanced NSCLC fall under the category of immune checkpoint inhibitors (ICIs) and are represented by: nivolumab, pembrolizumab, cemiplimab (anti PD-1 mAbs); atezolizumab, and durvalumab (anti PD-L1 mAbs); and ipilimumab and tremelimumab (anti CTLA-4, i.e., Cytotoxic T-Lymphocyte Antigen 4 mAbs).